Pattison M E, Lee S M, Ogden D A
Department of Internal Medicine, University of Arizona, Tucson.
Am J Kidney Dis. 1988 Jan;11(1):43-7. doi: 10.1016/s0272-6386(88)80173-2.
Continuous arteriovenous hemodiafiltration (CAVHD) offers a modified therapeutic approach to the patient with acute renal failure. The system employs a hollow-fiber dialyzer, whose perfusion is dependent on the patient's BP. Peritoneal dialysis solution is infused through the dialysate ports in a direction countercurrent to blood flow at a rate of 500 to 1,500 mL/h. Five complex patients with acute renal failure were treated with CAVHD for periods ranging from two to 40 days. Urea clearances approached 37 L/d, and in stable patients, the BUN was maintained at 40 to 60 mg/dL and serum creatinine 1.4 to 4.0 mg/dL. Ultrafiltration up to 1 L/h could be obtained without difficulty. CAVHD is a safe and technically simple procedure that is particularly suitable for hemodynamically unstable patients with ongoing needs for fluid removal.
持续动静脉血液透析滤过（CAVHD）为急性肾衰竭患者提供了一种改良的治疗方法。该系统采用中空纤维透析器，其灌注依赖于患者的血压。腹膜透析液通过透析液端口以500至1500 mL/h的速率向与血流相反的方向输注。5例急性肾衰竭的复杂患者接受了CAVHD治疗，治疗时间为2至40天。尿素清除率接近37 L/d，在病情稳定的患者中，血尿素氮维持在40至60 mg/dL，血清肌酐维持在1.4至4.0 mg/dL。可以轻松实现高达1 L/h的超滤。CAVHD是一种安全且技术上简单的操作，特别适合有持续液体清除需求的血流动力学不稳定患者。
